Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donald William Kufe, M.D.

Title
Institution
Department
Address
Phone

Overview
The Kufe laboratory identified the human DF3/MUC1 carcinoma-associated protein in the early 1980s. Initial studies demonstrated that MUC1 is aberrantly overexpressed in >90% of human breast cancers. Subsequent work by multiple laboratories showed that MUC1 is expressed at elevated levels by diverse carcinomas and certain hematologic malignancies. Estimates indicate that MUC1 is overexpressed in about 900,000 of the 1.4 million tumors diagnosed each year in the United States.

MUC1 is translated as a single polypeptide that undergoes autocleavage into two subunits (MUC1-N and MUC1-C) that in turn form a stable heterodimer at the apical membrane of normal epithelial cells. Early research on MUC1 focused on the shed MUC1-N mucin component and led to development of the CA15-3 assay to monitor circulating levels of this subunit as a tumor biomarker. Subsequent work then turned to the MUC1-C transmembrane subunit as the potential link between its overexpression and carcinogenesis. Indeed, the MUC1-C cytoplasmic domain was shown to be sufficient to induce transformation.

With transformation and loss of polarity, MUC1-C associates with EGFR, ErbB2 and other receptor tyrosine kinases at the cell membrane. MUC1-C also localizes to the cytoplasm of transformed cells and is targeted to the nucleus and mitochondria. The MUC1-C cytoplasmic domain directly contributes to the regulation of effectors, such as p53, ß-catenin, NF-kappaB and STATs, that have been linked to transformation. The MUC1-C cytoplasmic domain also functions as a substrate for EGFR, MET, Src family members, c-Abl and GSK3ß supporting a role in diverse signaling pathways.

These findings have provided support for a model in which human tumors overexpress MUC1-C to exploit its role in promoting growth and survival. In addition, the overexpression of MUC1-C in a substantial number of human malignancies has established it as a highly attractive target for the development of targeted agents.

Translational research in the Kufe laboratory has been focused on the development of approaches that block MUC1-C subunit function with soluble receptors and antibodies against the MUC1-C extracellular domain. The demonstration that MUC1-C transforming function is dependent on the formation of oligomers has also provided the experimental framework for designing agents, such as cell-penetrating peptides and small molecules, that block its oligomerization. Based on this work, the first-in-man MUC1-C inhibitor, designated GO-203, has entered Phase I evaluation in patients with refractory solid tumors.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01CA233084 (KUFE, DONALD W. ;WONG, KWOK KIN) Sep 20, 2018 - Aug 31, 2023
    NIH
    MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
    Role: Principal Investigator
  2. R21CA229716 (KUFE, DONALD W.) Jul 1, 2018 - Jun 30, 2020
    NIH
    Targeting the MUC1-C Oncoprotein in Colitis-Associated Colorectal Cancer
    Role: Principal Investigator
  3. R21CA216553 (KUFE, DONALD W.) Mar 16, 2017 - Feb 28, 2019
    NIH
    Immunotherapeutic Approaches Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
    Role: Principal Investigator
  4. UM1CA186709 (SHAPIRO, GEOFFREY I) Mar 13, 2014 - Feb 28, 2023
    NIH
    Dana?Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
    Role: Co-Principal Investigator
  5. R01CA166480 (KUFE, DONALD W.) Apr 1, 2012 - Mar 31, 2022
    NIH
    MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Kufe's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (1473)
Explore
_
Co-Authors (105)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.